Identification
Instrument name
BIOCARTIS
Symbol
BCART
ISIN code
BE0974281132
Exchange / Market
Euronext
Trading location
Brussels
Products family
Stocks
Capitalization compartment
Compartment B
ICB
Health Care Providers
Website address
http://www.biocartis.com
Operation
IPO date
Issue type
Initial Public offering
Cat├ęgorie
IPO
Price range
EUR 10.00 - EUR 11.50

Company profile

Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes. Net sales by source of income are mainly distributed between products sales (67.8%) and sale of collaboration services (29.9%; especially research and development services).

Source: Cofisem - Last Update: 11 Sep 2019
Key Executives
Chief Executive Officer Herman Verrelst
Chief Financial Officer Ewoud Welten
Investor Relations Director Renate Degrave
Source: Cofisem - Last Update: 11 Sep 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales 27,811 20,957 12,098 13,334 8,478
Income from ordinary activities 27,811 20,957 12,098 13,334 8,478
Operating income -46,860 -43,589 -50,171 -39,655 -29,173
Cost (net) of financial indebtedness -1,358 -1,248 -368 -668 -863
Equity-accounted companies' contribution to results
Net profit from discontinued activities 19,472
Net income -48,153 -41,960 -49,777 -39,797 -9,715
Net income (Group share) -48,153 -41,960 -49,777 -39,797 -9,118
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 11 Sep 2019
Shareholder information
Free float 61.00 %
Johnson & Johnson Innovation - JJDC 11.50 %
OppenheimerFunds Inc 9.40 %
Debiopharm Innovation Fund 8.30 %
Sycomore Asset Management SA 5.20 %
ParticipatieMaatschappij Vlaanderen 4.60 %
Source: Cofisem - Last Update: 08 Apr 2019